Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Authors
Ellen M. Basu (ORCID: https://orcid.org/0000-0002-4555-220X)
Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Ellen M. Basu, Audrey Mauguen, Stephen S. Roberts, Nai‐Kong V. Cheung et al.
Journal
Journal of Hematology & Oncology
Topics
Neuroblastoma Research and Treatments
article
Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Ellen M. Basu, Audrey Mauguen, Stephen S. Roberts, Nai‐Kong V. Cheung, Brian H. Kushner, Shakeel I. Modak
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Hematology & OncologyVol. 18(1)
Institutions
Memorial Sloan Kettering Cancer Center (US), Oregon Health & Science University (US)